P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL - T. Facon; T. Plesner; S. Usmani; S. Kumar; N. Bahlis; C. Hulin; R. Orlowski; H. Nahi; P. Mollee; K. Ramasamy; M. Roussel; A. Jaccard; et al. (HemaSphere, 2023)